Otonomy
Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.
Programs by Stage
Trial / Program Status
Modality Mix
Indication Coverage
Program Types
Population Tags
Strong-Evidence Records
0 recordsChecked Records With Caveats
6 checked · 0 open checksSustained-exposure intratympanic NMDA receptor antagonist formulation intended to reduce acute inner-ear tinnitus.
Sustained-exposure intratympanic formulation of BDNF intended to repair cochlear synapses and improve speech-in-noise performance.
AAV-based gene therapy program designed to restore hearing in patients with GJB2 mutation-associated congenital hearing loss.
Sustained-exposure intratympanic dexamethasone thermosensitive gel designed to maintain local steroid exposure in the inner ear for Meniere disease symptoms and other otologic indications.
Local small-molecule regenerative program intended to repair or regenerate cochlear hair cells damaged by noise, aging, or ototoxic chemicals.
Novel proprietary otoprotection molecule program intended to prevent cisplatin-induced hearing loss without protecting tumors.